Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report issued on Sunday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Down 2.2 %

Shares of NASDAQ EVOK opened at $4.96 on Friday. The firm has a market cap of $7.37 million, a PE ratio of -0.45 and a beta of 0.16. The company’s fifty day simple moving average is $4.95 and its 200 day simple moving average is $5.30. Evoke Pharma has a 12-month low of $3.54 and a 12-month high of $14.04.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. bought a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma as of its most recent SEC filing.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.